Quantitative Fundus Autofluorescence in HCQ Retinopathy.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 09 2020
Historique:
entrez: 25 9 2020
pubmed: 26 9 2020
medline: 1 4 2021
Statut: ppublish

Résumé

To increase our understanding of the mechanisms underlying hydroxychloroquine (HCQ) retinopathy, analyses by quantitative fundus autofluorescence (qAF) and near-infrared fundus autofluorescence (NIR-AF) were compared to results obtained by recommended screening tests. Thirty-one patients (28 females, 3 males) were evaluated with standard automated perimetry and spectral domain optical coherence tomography (SD-OCT); 28 also had multifocal electroretinography (mfERG). Measurement of short-wavelength fundus autofluorescence (SW-AF) by qAF involved the use of an internal fluorescent reference and intensity measurements in eight concentric segments at 7° to 9° eccentricity. For semiquantitative analysis of NIR-AF, intensities were acquired along a vertical axis through the fovea. Four of 15 high-dose (total dose >1000 g, daily dose >5.0 mg/kg) patients and one of 16 low-dose (total dose <1000 g, daily dose 4.4 mg/kg) patients were diagnosed with HCQ-associated retinopathy based on abnormal 10-2 visual fields, SD-OCT, and SW-AF imaging. Three of the high-dose patients also had abnormal mfERG results. Of the five patients exhibiting retinopathy, two had qAF color-coded images revealing higher intensities inferior, nasal, and lateral to the fovea. The abnormal visual fields also exhibited superior-inferior differences. Mean NIR-AF gray-level intensities were increased in four high-dose patients with no evidence of retinopathy. In two patients with retinopathy, NIR-AF intensity within the parafovea was below the normal range. One high-dose patient (6.25 mg/kg) had only abnormal mfERG results. These findings indicate that screening for HCQ retinopathy should take into consideration superior-inferior differences in susceptibility to HCQ retinopathy.

Identifiants

pubmed: 32976563
pii: 2770837
doi: 10.1167/iovs.61.11.41
pmc: PMC7521180
doi:

Substances chimiques

Antirheumatic Agents 0
Hydroxychloroquine 4QWG6N8QKH

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41

Subventions

Organisme : NEI NIH HHS
ID : P30 EY019007
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY009076
Pays : United States

Références

Ophthalmology. 2015 Jan;122(1):110-6
pubmed: 25182842
Doc Ophthalmol. 2009 Feb;118(1):69-77
pubmed: 19030905
Clin Ophthalmol. 2010 Oct 21;4:1151-8
pubmed: 21060664
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):5029-39
pubmed: 26230768
Invest Ophthalmol Vis Sci. 2012 Aug 07;53(9):5190-7
pubmed: 22786896
Graefes Arch Clin Exp Ophthalmol. 2005 Oct;243(10):1018-27
pubmed: 15906064
Invest Ophthalmol Vis Sci. 2014 Jul 11;55(9):5643-52
pubmed: 25015357
JAMA Ophthalmol. 2014 Sep;132(9):1105-12
pubmed: 24922444
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):585-91
pubmed: 23287793
Retina. 2019 Mar;39(3):473-484
pubmed: 30741731
Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2841-52
pubmed: 24677105
FEBS Lett. 1976 Apr 15;64(1):231-5
pubmed: 5310
APMIS. 2002 Jun;110(6):481-9
pubmed: 12193209
Ophthalmology. 2015 Feb;122(2):345-55
pubmed: 25283059
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):775-82
pubmed: 8603862
J Cell Biol. 1974 Nov;63(2 Pt 1):430-40
pubmed: 4607946
Pharmacogenomics. 2017 Oct;18(15):1393-1400
pubmed: 28975866
Exp Eye Res. 1986 Dec;43(6):915-28
pubmed: 3817032
JAMA Ophthalmol. 2017 Dec 1;135(12):1330-1338
pubmed: 29075777
Br J Ophthalmol. 2012 May;96(5):723-9
pubmed: 22328813
Ophthalmology. 2015 Feb;122(2):356-66
pubmed: 25444344
Doc Ophthalmol. 2015 Feb;130(1):13-23
pubmed: 25502494
Br J Ophthalmol. 2019 Nov;103(11):1600-1604
pubmed: 30819690
JAMA Ophthalmol. 2013 Sep;131(9):1187-97
pubmed: 23887202
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1843-1855
pubmed: 28358950
Lupus. 2018 Sep;27(10):1616-1623
pubmed: 29954281
BMC Ophthalmol. 2015 Mar 06;15:18
pubmed: 25884411
JAMA Ophthalmol. 2014 Dec;132(12):1453-60
pubmed: 25275721
Arch Ophthalmol. 2012 Apr;130(4):461-9
pubmed: 22159170
Graefes Arch Clin Exp Ophthalmol. 1999 Jan;237(1):1-9
pubmed: 9951634
Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):865-72
pubmed: 26311262
Arch Ophthalmol. 1991 Jan;109(1):84-91
pubmed: 1987955
Curr Eye Res. 2004 Apr;28(4):277-84
pubmed: 15259297
Ophthalmology. 2016 Jun;123(6):1386-94
pubmed: 26992838
J Pharm Sci. 2016 Feb;105(2):884-890
pubmed: 26429523
Clin Exp Ophthalmol. 2010 Aug;38(6):597-604
pubmed: 20456441
Br J Ophthalmol. 2014 Feb;98(2):200-6
pubmed: 24187053
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7274-85
pubmed: 26551331
Rheumatology (Oxford). 2016 Jun;55(6):957-67
pubmed: 26428520
Invest Ophthalmol Vis Sci. 2015 May;56(5):3159-70
pubmed: 26024099
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2165-2172
pubmed: 31108547
Ophthalmology. 2015 Jun;122(6):1252-6
pubmed: 25712474
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3544-50
pubmed: 12882805
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3531-8
pubmed: 16877425
Am J Ophthalmol. 2007 May;143(5):801-809
pubmed: 17336914
J Opt Soc Am A Opt Image Sci Vis. 2007 Jul;24(7):1842-57
pubmed: 17728807
Retina. 2019 Mar;39(3):492-501
pubmed: 30550532
Invest Ophthalmol Vis Sci. 2013 Aug 21;54(8):5684-93
pubmed: 23860757
Br J Ophthalmol. 2008 Dec;92(12):1653-5
pubmed: 18829634
Invest Ophthalmol Vis Sci. 2014 Mar 13;55(3):1471-82
pubmed: 24526438
J Biol Chem. 2018 Dec 14;293(50):19400-19410
pubmed: 30352873

Auteurs

Vivienne C Greenstein (VC)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Department of Ophthalmology, New York University School of Medicine, New York, New York, United States.

Jose Ronaldo Lima de Carvalho (JR)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.

Rait Parmann (R)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.

Luz Amaro-Quireza (L)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.

Winston Lee (W)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.

Donald C Hood (DC)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Deparment of Psychology, Columbia University, New York, New York, United States.

Stephen H Tsang (SH)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, United States.

Janet R Sparrow (JR)

Department of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH